Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lifecare AS ( (DE:LFC0) ) has issued an update.
Lifecare ASA has initiated formal preparations for achieving CE marking of its Continuous Glucose Monitoring (CGM) system as a regulated medical device, aiming for completion by the end of 2026. This milestone signifies Lifecare’s progress towards market readiness, highlighting its commitment to regulatory compliance and quality standards, which strengthens its position in the MedTech industry and signals readiness to stakeholders and partners.
More about Lifecare AS
Lifecare ASA is a MedTech company based in Bergen, Norway, specializing in the development of next-generation Continuous Glucose Monitoring (CGM) technology for diabetes management. The company focuses on utilizing osmotic pressure as a sensing principle to monitor various body analytes and molecules, aiming to bring advanced CGM systems to market for both humans and pets.
Average Trading Volume: 150,718
Current Market Cap: NOK202M
For a thorough assessment of LFC0 stock, go to TipRanks’ Stock Analysis page.